Fidelity Investments’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-19,331
| Closed | -$38.5K | – | 5468 |
|
|
2025
Q2 | $38.5K | Buy |
19,331
+6,931
| +56% | +$12.7K | ﹤0.01% | 4016 |
|
|
2025
Q1 | $18K | Sell |
12,400
-3,459
| -22% | -$6.39K | ﹤0.01% | 4264 |
|
|
2024
Q4 | $32.8K | Buy |
15,859
+6,849
| +76% | +$12.9K | ﹤0.01% | 4025 |
|
|
2024
Q3 | $15.9K | Buy |
9,010
+8,456
| +1,526% | +$21.7K | ﹤0.01% | 4278 |
|
|
2024
Q2 | $8.01K | Buy |
554
+58
| +12% | +$797 | ﹤0.01% | 4406 |
|
|
2024
Q1 | $8.25K | Buy |
496
+238
| +92% | +$3.81K | ﹤0.01% | 4345 |
|
|
2023
Q4 | $4.14K | Sell |
258
-801
| -76% | -$10.6K | ﹤0.01% | 4505 |
|
|
2023
Q3 | $14.2K | Buy |
1,059
+724
| +216% | +$10.2K | ﹤0.01% | 3973 |
|
|
2023
Q2 | $5.76K | Sell |
335
-172
| -34% | -$2.67K | ﹤0.01% | 4321 |
|
|
2023
Q1 | $8.38K | Buy |
507
+337
| +198% | +$5.39K | ﹤0.01% | 4196 |
|
|
2022
Q4 | $2.84K | Sell |
170
-73
| -30% | -$1.32K | ﹤0.01% | 4420 |
|
|
2022
Q3 | $4K | Buy |
243
+228
| +1,520% | +$3.31K | ﹤0.01% | 4388 |
|
|
2022
Q2 | $0 | Buy |
+15
| New | +$178 | ﹤0.01% | 5179 |
|
Fidelity Investments's HLVX Position: Q3 2025 in Review
Fidelity Investments sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 19,331 shares — an estimated $38.5K sold.
Fidelity Investments first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $38.5K in Q2 2025. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Fidelity Investments reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Fidelity Investments sold 19,331 HilleVax shares in Q3 2025, an estimated $38.5K.
- Fidelity Investments first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Fidelity Investments's HilleVax position peaked at $38.5K in Q2 2025.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.